Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma

Document Type: Research Articles

Authors

1 Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Objective: Brain tumors are of high mortality and morbidity for which there is still no cure. The TNF family cytokine,
A Proliferation Inducing Ligand (APRIL), is shown to help proliferation and development of tumor cells. We assessed
serum levels of APRIL in patients with glioma, meningioma and schwannoma in comparison to healthy individuals.
Methods: Peripheral blood samples of 68 patients with brain tumors, divided into three groups of gliomas (n=25),
meningiomas (n=30) and schwannomas (n=13), as well as 45 healthy individuals were obtained. Serum samples were
prepared and stored in -40°C until usage. Using a commercial ELISA method, APRIL concentration was measured in
each serum sample. The obtained data were then analyzed using SPSS software. Results: APRIL serum levels were
higher in all patients compared to the controls (P<0.001). Moreover, APRIL serum levels were higher in each of the
tumor bearing groups (gliomas, meningiomas and schwannomas) in comparison to the controls (P<0.001, <0.001
and =0.001, respectively). Comparing APRIL between the patients groups showed no significant difference. Age and
gender showed no significant correlation with serum APRIL levels, although the age of patients in glioma group was
significantly lower than controls (P=0.017). The serum APRIL levels in gliomas with histological grade showed no
difference, but in meningiomas, it was lower in tumors with higher grades (P= 0.011). Conclusion: Increased serum
levels of APRIL in patients with meningioma and schwannoma as well as glioma may indicate a common role of this
cytokine in brain tumors.

Keywords

Main Subjects